Skip to main content

Advertisement

SpringerLink
Log in

Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis

  • Original Paper
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of this study was to determine the performance of antibodies against mutated citrullinated vimentin (anti-MCV) in comparison with antibodies to cyclic citrullinated peptides (anti-CCP) in patients with rheumatoid arthritis (RA). Serum levels of anti-MCV and anti-CCP were determined in 193 patients with RA and 332 controls, and sensitivity and specificity were calculated. In a separate analysis of 86 patients, the anti-MCV levels were compared to disease activity. Sensitivity of anti-MCV versus anti-CCP was 71.5 and 69.4%, specificity was 81.3 and 97.6%, respectively. The ROC curves showed higher specificity and an advantage of anti-CCP. In seronegative RA patients the sensitivity of anti-MCV was superior over anti-CCP. Anti-MCV positivities also occurred in systemic lupus erythematosus and Sjoegren’s syndrome. In a subgroup of 86 RA patients we found a significant correlation between anti-MCV and disease activity. Anti-MCV appears to be an important marker for the diagnosis of RA, and correlates also with disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ACR:

American College of Rheumatology

ACPA:

Anti-citrullinated peptides antibodies

Anti-CCP:

Antibodies against cyclic citrullinated peptide

Anti-MCV:

Antibodies against mutated citrullinated vimentin

Anti-Sa:

Antibodies against Sa-antigen

CRP:

C-reactive protein

DAS:

Disease activity score

ELISA:

Enzyme linked immuno sorbent assay

HLA-DR4:

Human leucocyte antigen

RA:

Rheumatoid arthritis

RF:

Rheumatoid factor

ROC-curve:

Receiver operating characteristics curve

SLE:

Systemic lupus erythematosus

References

  1. Hassfeld W, Steiner G, Graninger W et al (1999) Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 32:199–203. doi:10.1093/rheumatology/32.3.199

    Article  Google Scholar 

  2. Boire G, Cossette P, Brum-Fernandes AJ et al (2005) Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:592–603. doi:10.1186/ar1719

    Article  Google Scholar 

  3. El-Gabalawy HS, Wilkins JA (2004) Anti-Sa antibodies: prognostic and pathogenic significance to rheumatoid arthritis. Arthritis Res Ther 6:86–89. doi:10.1186/ar1171

    Article  PubMed  CAS  Google Scholar 

  4. Hueber W, Hassfeld W, Smolen JS et al (1999) Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology 38:155–159. doi:10.1093/rheumatology/38.2.155

    Article  PubMed  CAS  Google Scholar 

  5. Lopez-Longo F-J, Rodriguez-Mahou M, Sanchez-Ramon S et al (2006) Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. J Rheumatol 33:1476–1481

    PubMed  CAS  Google Scholar 

  6. Vossenaar ER, Després N, Lapointe E et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150. doi:10.1186/ar1149

    Article  PubMed  CAS  Google Scholar 

  7. Rantapaa-Dahlquist S, deJong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749. doi:10.1002/art.11223

    Article  Google Scholar 

  8. Dejaco C, Klotz W, Larcher H et al (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8:R119. doi:10.1186/ar2008

    Article  PubMed  Google Scholar 

  9. Nell VPK, Machold K, Stamm TA et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736. doi:10.1136/ard.2005.035691

    Article  PubMed  CAS  Google Scholar 

  10. Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511. doi:10.1002/art.22817

    Article  PubMed  CAS  Google Scholar 

  11. Hartung WE, Schölmerich J, Fredenhagen G et al (2006) Die Bedeutung des mutierten citrullinierten Vimentins (Anti-MCV) für die Differentialdiagnostik der Arthritis. Z Rheumatol 65(Suppl 1):S30. doi:10.1007/s00393-006-0125-5

    Google Scholar 

  12. Coenen D, Verschueren P, Westhovens R et al (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53:498–504. doi:10.1373/clinchem.2006.078063

    Article  PubMed  CAS  Google Scholar 

  13. Soós L, Szekanecz Z, Szabó Z et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663

    PubMed  Google Scholar 

  14. Rönnelid J, Mullazehi M, Mathsson L (2007) Differential prognostic impact of autoantibodies and inflammation markers in early rheumatoid arthritis. In: Conrad K, Chan EKL, Fritzler MJ, Sack U, Shoenfeld Y, Wiik AS (eds) Autoantigens, Autoantibodies, Autoimmunity, vol 5. Report on the 8th Dresden Symposium on autoantibodies. 12–15 September 2007, pp 389–400

  15. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

D.I. Fabian (Orgentech Company) provided the kits for analysis. Funding for this work was given by Ludwig Boltzmann Cluster (Rheumatology, Balneology and Rehabilitation), Institute of Rheumatology of the Kurstadt Baden, Austria.

Conflict of interest statement

The authors declare that they do not have competing interests.

Author information

Authors and Affiliations

  1. Institute for Rheumatology of the Kurstadt Baden RSKA Baden of the NOEGKK and Ludwig Boltzmann Cluster Rheumatology, Balneology and Rehabilitation, Forschungsstelle for Epidemiology of Rheumatic Diseases, Sauerhofstraße 9-15, 2500, Baden, Austria

    Ernst Wagner

  2. Institute for Rheumatology of the Kurstadt Baden 4th Medical Department and Ludwig Boltzmann Institute of Osteology, Hanusch Krankenhaus of WGKK, Vienna, Austria

    M. Skoumal

  3. Central Laboratory, Wilhelminen Hospital, Vienna, Austria

    P. M. Bayer

  4. 4th Medical Department and Ludwig Boltzmann Institute of Osteology, Hanusch Krankenhaus of WGKK and AUVA Trauma Centre Meidling, Vienna, Austria

    K. Klaushofer

Authors
  1. Ernst Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Skoumal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. M. Bayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Klaushofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernst Wagner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagner, E., Skoumal, M., Bayer, P.M. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 29, 1315–1321 (2009). https://doi.org/10.1007/s00296-009-0854-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-0854-2

Keywords

Search

Navigation